Our founders’ insights and achievements
![](https://assets-global.website-files.com/64e71e5dd16c75b9e6ce8b6d/6501be6f6e9d382ecda4fb34_PIC.png)
![](https://assets-global.website-files.com/64e71e5dd16c75b9e6ce8b75/65c4c7304d119171682efb18_inbiomotion_sl_logo.jpg)
Inbiomotion and Source BioScience sign an exclusive agreement for MAF Test® in United Kingdom and Ireland
![](https://assets-global.website-files.com/64e71e5dd16c75b9e6ce8b6d/6501be6f6e9d382ecda4fb34_PIC.png)
![](https://assets-global.website-files.com/64e71e5dd16c75b9e6ce8b75/65094ef2e43608bc6dbded04_Aboleris-news-1.jpg)
Criteria Bio Ventures leads €27 Mn round in AbolerIS Pharma to advance therapies against autoimmune diseases
![](https://assets-global.website-files.com/64e71e5dd16c75b9e6ce8b6d/6501be6f6e9d382ecda4fb34_PIC.png)
![](https://assets-global.website-files.com/64e71e5dd16c75b9e6ce8b75/64f9dd2d46e85e03b471386a_caliyx-logo-color345.png)
Minoryx gains FDA approval to initiate a Phase 3 clinical trial in patients with cerebral Adrenoleukodystrophy
![](https://assets-global.website-files.com/64e71e5dd16c75b9e6ce8b6d/6501be6f6e9d382ecda4fb34_PIC.png)
![](https://assets-global.website-files.com/64e71e5dd16c75b9e6ce8b75/64f9d851ecf1dfd3d98caa07_nexus125.jpg)
Minoryx presents positive interim results from NEXUS registration study for leriglitazone targeting pediatric ALD patients with cerebral adrenoleukodystrophy (cALD)
![](https://assets-global.website-files.com/64e71e5dd16c75b9e6ce8b6d/6501be6f6e9d382ecda4fb34_PIC.png)
![](https://assets-global.website-files.com/64e71e5dd16c75b9e6ce8b75/64f9d82c25768134265d409e_lancet-neurology-banner-grande2615.jpg)
The Lancet Neurology publishes results from Minoryx Therapeutics Phase 2/3 ADVANCE clinical trial of leriglitazone in X-linked Adrenoleukodystrophy
![](https://assets-global.website-files.com/64e71e5dd16c75b9e6ce8b6d/6501be6f6e9d382ecda4fb34_PIC.png)
![](https://assets-global.website-files.com/64e71e5dd16c75b9e6ce8b75/64f9d7f3a3cc48c71e5e673e_neuraxpharm133.jpg)
Minoryx and Neuraxpharm announce a strategic alliance to provide a new therapy for rare CNS disease patients in Europe
![](https://assets-global.website-files.com/64e71e5dd16c75b9e6ce8b6d/6501be6f6e9d382ecda4fb34_PIC.png)
![](https://assets-global.website-files.com/64e71e5dd16c75b9e6ce8b75/64f9d7c4c1d319a2ae423d1e_Web.jpg)
Positive results from AELIX’ HIV therapeutic vaccine clinical study AELIX-002 published in Nature Medicine
![](https://assets-global.website-files.com/64e71e5dd16c75b9e6ce8b6d/6501be6f6e9d382ecda4fb34_PIC.png)
![](https://assets-global.website-files.com/64e71e5dd16c75b9e6ce8b75/64f9d78985ca19f284b390cf_ema-amsterdam936.jpg)
Minoryx‘s Marketing Authorization Application for its lead candidate leriglitazone validated by EMA for orphan indication X-linked Adrenoleukodystrophy (X-ALD)
![](https://assets-global.website-files.com/64e71e5dd16c75b9e6ce8b6d/6501be6f6e9d382ecda4fb34_PIC.png)
![](https://assets-global.website-files.com/64e71e5dd16c75b9e6ce8b75/64f9d75881527b3df4ee40b8_marc-offices-mataro759.jpg)
Minoryx raises €51 million to support Marketing Authorization Application and launch preparations for X-linked Adrenoleukodystrophy (X-ALD) therapy
![](https://assets-global.website-files.com/64e71e5dd16c75b9e6ce8b6d/6501be6f6e9d382ecda4fb34_PIC.png)
![](https://assets-global.website-files.com/64e71e5dd16c75b9e6ce8b75/65017d2e0926af0ccb32fb9c_Sanifit.jpg)
Caixa Capital Risc leads sale of Sanifit Therapeutics to Vifor Pharma with upfront payment of €205M
![](https://assets-global.website-files.com/64e71e5dd16c75b9e6ce8b6d/6501be6f6e9d382ecda4fb34_PIC.png)
Medlumics raises €14M in a Series E financing co-led by Asabys Partners, VI Partners and CDTI Innvierte, together with existing investors Andera Partners, Caixa Capital Risc and Innogest
![](https://assets-global.website-files.com/64e71e5dd16c75b9e6ce8b6d/6501be6f6e9d382ecda4fb34_PIC.png)
Minoryx Therapeutics and Sperogenix Therapeutics enter into an exclusive license agreement to develop and commercialize leriglitazone in mainland China, Hong Kong and Macau
![](https://assets-global.website-files.com/64e71e5dd16c75b9e6ce8b6d/6501be6f6e9d382ecda4fb34_PIC.png)
Caixa Capital Risc is leading the largest operation in the biotech sector in Spain, with a €55 million financing round in Sanifit
![](https://assets-global.website-files.com/64e71e5dd16c75b9e6ce8b6d/6501be6f6e9d382ecda4fb34_PIC.png)
Minoryx Therapeutics announces first patient dosed in the FRAMES phase 2 trial in Friedreich’s Ataxia
![](https://assets-global.website-files.com/64e71e5dd16c75b9e6ce8b6d/6501be6f6e9d382ecda4fb34_PIC.png)
Minoryx Therapeutics receives approval from Spanish Regulatory Agency to initiate phase 2 study in Friedreich’s Ataxia
![](https://assets-global.website-files.com/64e71e5dd16c75b9e6ce8b6d/6501be6f6e9d382ecda4fb34_PIC.png)
AELIX Therapeutics and Gilead Sciences Enter into a Clinical Research Collaboration Agreement to Evaluate a Therapeutic Vaccine and TLR7 Agonist Regimen for HIV Cure
![](https://assets-global.website-files.com/64e71e5dd16c75b9e6ce8b6d/6501be6f6e9d382ecda4fb34_PIC.png)
NuMat Medtech secures a €530,000 round of investment
![](https://assets-global.website-files.com/64e71e5dd16c75b9e6ce8b6d/6501be6f6e9d382ecda4fb34_PIC.png)
Minoryx Therapeutics raises €21.3M in Series B funding round
![](https://assets-global.website-files.com/64e71e5dd16c75b9e6ce8b6d/6501be6f6e9d382ecda4fb34_PIC.png)
![](https://assets-global.website-files.com/64e71e5dd16c75b9e6ce8b75/6501f7404edf9b61ccb408d1_covid-19-protocols-tile.jpg)
QIAGEN enters into agreement to acquire STAT-Dx, a Caixa Capital Risc portfolio company
![](https://assets-global.website-files.com/64e71e5dd16c75b9e6ce8b6d/6501be6f6e9d382ecda4fb34_PIC.png)
MedLumics, a company owned by “la Caixa” and Ysios Capital, closes a financing round of 34.4 million euros
![](https://assets-global.website-files.com/64e71e5dd16c75b9e6ce8b6d/6501be6f6e9d382ecda4fb34_PIC.png)
Minoryx Therapeutics Initiates Phase 1 clinical trial of MIN-102
![](https://assets-global.website-files.com/64e71e5dd16c75b9e6ce8b6d/6501be6f6e9d382ecda4fb34_PIC.png)
Stat Diagnostica announces 25 Million Euros in Series C Financing
![](https://assets-global.website-files.com/64e71e5dd16c75b9e6ce8b6d/6501be6f6e9d382ecda4fb34_PIC.png)
![](https://assets-global.website-files.com/64e71e5dd16c75b9e6ce8b75/650200e82f0f4f498afcae35_foto-news-1980%402x.jpg)
”la Caixa” leads an investment round in Inbiomotion with the participation of Ysios Capital
![](https://assets-global.website-files.com/64e71e5dd16c75b9e6ce8b6d/6501be6f6e9d382ecda4fb34_PIC.png)
Minoryx Therapeutics appoints Dr. Khalid Islam as chairman of the board of directors
![](https://assets-global.website-files.com/64e71e5dd16c75b9e6ce8b6d/6501be6f6e9d382ecda4fb34_PIC.png)
![](https://assets-global.website-files.com/64e71e5dd16c75b9e6ce8b75/6501f881f296ae51facf7888_aelix-group-931x568.jpg)
Aelix Therapeutics completes Series A funding of €11.5M ($12.7M) for therapeutic HIV vaccine
![](https://assets-global.website-files.com/64e71e5dd16c75b9e6ce8b6d/6501be6f6e9d382ecda4fb34_PIC.png)
PlantResponse Biotech raises 5.7 Million € in Series A funding
![](https://assets-global.website-files.com/64e71e5dd16c75b9e6ce8b6d/6501be6f6e9d382ecda4fb34_PIC.png)
Minoryx Therapeutics completes Series A funding of €19.4M ($21.7M)
![](https://assets-global.website-files.com/64e71e5dd16c75b9e6ce8b6d/6501be6f6e9d382ecda4fb34_PIC.png)
Sanifit raises €36.6M ($41.3M) in Series C financing round
![](https://assets-global.website-files.com/64e71e5dd16c75b9e6ce8b6d/6501be6f6e9d382ecda4fb34_PIC.png)
”la Caixa” leads a 1.6 million Euro round in Minoryx
![](https://assets-global.website-files.com/64e71e5dd16c75b9e6ce8b6d/6501be6f6e9d382ecda4fb34_PIC.png)
"la Caixa" leads 3.6 million euro financing round in Sanifit
![](https://assets-global.website-files.com/64e71e5dd16c75b9e6ce8b6d/6501be6f6e9d382ecda4fb34_PIC.png)
nLife Therapeutics recibe 350.000 dólares americanos de la Fundación Michael J. Fox para la investigación de la enfermedad de Parkins
![](https://assets-global.website-files.com/64e71e5dd16c75b9e6ce8b6d/6501be6f6e9d382ecda4fb34_PIC.png)
”la Caixa” and CRB Inverbío invest three million Euros in Nuubo, specialised in wearable technologies with medical applications
![](https://assets-global.website-files.com/64e71e5dd16c75b9e6ce8b6d/6501be6f6e9d382ecda4fb34_PIC.png)
Laboratoris Sanifit begins the fight against calciphylaxis
![](https://assets-global.website-files.com/64e71e5dd16c75b9e6ce8b6d/6501be6f6e9d382ecda4fb34_PIC.png)
Minoryx takes a step forward in the treatment of rare diseases
![](https://assets-global.website-files.com/64e71e5dd16c75b9e6ce8b6d/6501be6f6e9d382ecda4fb34_PIC.png)
STAT-Diagnostica closes a 17 million euro financing round and brings in leading international investors
![](https://assets-global.website-files.com/64e71e5dd16c75b9e6ce8b6d/6501be6f6e9d382ecda4fb34_PIC.png)
MedLumics Announces “BiopsyPen Project” with €3.6M EU in Funding
![](https://assets-global.website-files.com/64e71e5dd16c75b9e6ce8b6d/6501be6f6e9d382ecda4fb34_PIC.png)
"la Caixa" and Inveready invest in Minoryx